The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD Registry

BACKGROUND: The impact of immune-modifying therapies on outcomes of coronavirus disease 2019 [COVID-19] is variable. The purpose of this study was to determine the impact of vedolizumab [VDZ], a gut-selective anti-integrin, on COVID-19 outcomes in inflammatory bowel disease [IBD] patients. METHODS:...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Crohns Colitis
Prif Awduron: Agrawal, Manasi, Zhang, Xian, Brenner, Erica J, Ungaro, Ryan C, Kappelman, Michael D, Colombel, Jean-Frederic
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Oxford University Press 2021
Pynciau:
Original Articles
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC8083188/
https://ncbi.nlm.nih.gov/pubmed/33884425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ecco-jcc/jjab071
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg